PART 1 - NYR Aus Peer Analysis, page-3

1. Firstly Wars444 you are comparing single assets in a single field in those comparisons, the only one that is of comparison is PYC as a platform. Compare global platforms which they are taken over in phase 1/2. NYR has already stated in their presentation this is a platform where the target and mechanism of action is already proven

2. phase 2 is a proof of concept where the target and mechanism of action is proven. NYR as stated in company presentation have already stated the target and mechanism of action is already proven. It’s why NYR rerated after Boehringer blockbuster results of p value of 0.002 and 100 percent response rates in over expression patients. Boehringer proved up this space before we spent a dollar. Hence why the coming up phase 2 is significantly de risked and so is the dozens of indications that literature and global papers have proven Xolatryp will work in

3. Dimitri is the company secretary and to ask him he knows nothing and won’t tell you nothing. I have never seen a company secretary ever leak out insider information to a random investor. Where you have to be looking is the top 20 and major shareholders pouring in millions and like the CWH poured in millions 1-2 months later major catalysts came in to rerate the stock. Company has specifically stated high impact catalysts are coming

4. IND is submitted after HREC approval that is correct and stated by the CEO at the AGM.

5. The only drug on your list that NYR can be compared to is PYC. PYC is actually the only platform you have mentioned with potential of the platform to generate dozens of different drugs for different indications. It is a 900 million market cap and has 3 drugs in phase 1 and 1 drug in phase 2 intern analysis. The potential of it creating more drugs from its platform is why it’s valued so much. The proof of concept of target and mechanism of action is not yet proven. However each drug needs to go through animal toxicology studies and safety studies that burn cash and take years. NYR is 170 million market cap on a platform where dozens of indications about to become 20 times larger in market size dollars compared to PYC where the safety and toxicology studies in animals is already done saving 10s of millions of dollars and years of development. Hence them announcing the oncology space over multiple indications treated simultaneously is the holy grail and a phase 2 asset everytime but the target and mechanism of action is already proven meaning end point is heavily de risked